The CholBiome line has been clinically shown to reduce elevated cholesterol and blood pressure levels.
ProBiotix Health, a subsidiary of microbiome-ingredients firm OptiBiotix Health (York, UK), has signed an exclusive deal to bring its CholBiome line of probiotic ingredients for cardiovascular health to the South Korean market.
ProBiotix will work with Inscobee, a public company on the Korean stock market which sells nutraceuticals through hospitals, retail stores, and e-commerce, to bring the ingredients to market. In a press release, ProBiotix notes that, “Over the past decade, there has been an increase in chronic disease in Korea, with a notable rise in cardiovascular diseases (CVDs). CVDs have become one of the leading causes of morbidity and mortality in Korea and in fact are the second most common cause of mortality in the country.”
The CholBiome line has been clinically shown to reduce elevated cholesterol and blood pressure levels. The ingredients feature the patented probiotic ingredient LPLDL, a strain of Lactobacillus plantarum. The ingredient “is a naturally occurring bacterium that harnesses the microbiome-liver axis to impact positively upon the gut microbiome,” OptiBiotix explains on its website. “Its outstanding ability to modulate bile acid metabolism is beneficial for heart health factors such as high blood pressure and high cholesterol, as well as other processes from liver function to glucose regulation and vitamin metabolism.”